Evidence map›Paper›PMID 36610075›Full record

ArticleBiostatistics (Oxford, England)2023

Flexible evaluation of surrogacy in platform studies.

Michael C Sachs, Erin E Gabriel, Alessio Crippa, Michael J Daniels

Abstract read
In one paragraph

Article in Biostatistics (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael C SachsDepartment of Public Health, Section of Biostatistics, University of Copenhagen, Øster Farimagsgade 5, 1353 København K, Denmark.ORCID 0000-0002-1279-8676
Erin E GabrielDepartment of Public Health, Section of Biostatistics, University of Copenhagen, Øster Farimagsgade 5, 1353 København K, Denmark.
Alessio CrippaDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, Stockholm 17177, Sweden.ORCID 0000-0002-2254-2420
Michael J DanielsDepartment of Statistics, University of Florida, Union Rd, Gainesville, FL 32603, USA.

Funding

Combining longitudinal cohort studies to examine cardiovascular risk factor trajectories across the adult lifespan and their association with diseaseR01HL158963 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DANIELS, MICHAEL J, SIDDIQUE, JUNED · 2021 to 2024
$2.3M
Bayesian machine learning for complex missing data and causal inference with a focus on cardiovascular and obesity studiesR01HL166324 · NHLBI · UNIVERSITY OF FLORIDA · PI Michael J Daniels · 2023 to 2026
$2.1M
NHLBI NIH HHS R01 HL158963NHLBI NIH HHS R01 HL166324NIH HHS R01 HL158963
6 · The paper itself

Abstract

Trial-level surrogates are useful tools for improving the speed and cost effectiveness of trials but surrogates that have not been properly evaluated can cause misleading results. The evaluation procedure is often contextual and depends on the type of trial setting. There have been many proposed methods for trial-level surrogate evaluation, but none, to our knowledge, for the specific setting of platform studies. As platform studies are becoming more popular, methods for surrogate evaluation using them are needed. These studies also offer a rich data resource for surrogate evaluation that would not normally be possible. However, they also offer a set of statistical issues including heterogeneity of the study population, treatments, implementation, and even potentially the quality of the surrogate. We propose the use of a hierarchical Bayesian semiparametric model for the evaluation of potential surrogates using nonparametric priors for the distribution of true effects based on Dirichlet process mixtures. The motivation for this approach is to flexibly model relationships between the treatment effect on the surrogate and the treatment effect on the outcome and also to identify potential clusters with differential surrogate value in a data-driven manner so that treatment effects on the surrogate can be used to reliably predict treatment effects on the clinical outcome. In simulations, we find that our proposed method is superior to a simple, but fairly standard, hierarchical Bayesian method. We demonstrate how our method can be used in a simulated illustrative example (based on the ProBio trial), in which we are able to identify clusters where the surrogate is, and is not useful. We plan to apply our method to the ProBio trial, once it is completed.

Indexed as

Clinical Trials as TopicBayes TheoremHumansTreatment OutcomeBayesian nonparametricsBiomarkersMultilevel modelProstate cancerSurrogate markersTrial-level surrogate

Identifiers

PMID36610075
PMCPMC10939396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.